ACS CAN advocates for policies that provide access to treatments and services people with cancer need for their care - including those who may be newly diagnosed, in active treatment and cancer survivors.
On July 3, 2025, Congress passed the final version of its 2025 budget reconciliation legislation. The American Cancer Society Cancer Action Network strongly opposed the health changes included in the bill, which the Congressional Budget Office estimates would reduce the number of people with health insurance by 10 million people by 2034 through major cuts to Medicaid and changes to Marketplace and other coverage.
The One Big Beautiful Bill Act (Pub. Law No. 119-21) prohibits states from auto-enrolling people into Marketplace plans (regardless of whether the Marketplace is state-based or federally run).
Nearly all (94%) cancer patients and survivors agree that it is important for patients and their providers to have the ability to choose the type of treatment and delivery that best suits their needs. Patients who have taken oral anti-cancer drugs rate their experience significantly better compared to experiences with IV infusions on several metrics including coping with side effects, time spent in provider visits, and quality of life.
Our latest Survivor Views survey finds that across party lines cancer patients and survivors oppose reducing funding for Medicaid (73%), and fewer than one-in-five support adding a work requirement for Medicaid (19%). The survey also finds overwhelming support for protecting coverage for those with preexisting conditions (81%), and explores questions related to allowing non-ACA plans in the marketplace, which a majority (65%) feel would be confusing.
Our latest survey finds that 86% of those receiving enhanced premium tax credits would have difficulty getting care if the credits expire at the end of 2025, and very few (25%) are aware of the enhanced credits expiring.
A majority of cancer patients and survivors struggle to afford cancer care and over 80% have had to make financial sacrifices to cover their health care expenses. This survey also reveals ways that affordability concerns can negatively impact care and treatment, and explores issues related to prescription drug coverage and pain management options.
Many cancer patients take multiple drugs as part of their treatment – often for many months or years. While drugs are not the only costly part of cancer treatment, finding ways to reduce these costs for patients and payers will significantly reduce the overall cost burden of cancer.
This Survivor Views survey examined access to and affordability of cancer care. Survivors report insurance-related barriers to obtaining prescriptions, and lower-income respondents in particular have difficulty affording them. 24% of respondents have received a surprise medical bill, 60% of which were more than $500.
Biological drugs, commonly referred to as biologics, are a class of drugs that are produced using a living system, such as a microorganism, plant cell, or animal cell. Like all drugs, biologics are regulated by the United States Food and Drug Administration (FDA).
For an individual with specific health care needs – like cancer patients and survivors – the drugs covered by a health plan and corresponding cost sharing for each drug is important information when choosing health insurance. However, to make an informed choice, formulary information must be disclosed to the individual.
ACS CAN supports the administration’s goal of improving market integrity and we are committed to policies that effectively address any waste, fraud, and abuse that exists in public health care programs.
The American Cancer Society Cancer Action Network (ACS CAN) appreciates the opportunity to comment on the Patient Protection and Affordable Care Act, HHS Notice of Benefit and Payment Parameters (NBPP) for plan year 2026.
In our latest survey, cancer patients and survivors overwhelmingly support extending financial assistance for people who purchase health coverage through the Affordable Care Act marketplace by a margin of nearly 12 to 1 (72% support, 6% oppose). The survey also finds 43% would not be able to afford their plan without the enhanced tax credits, 30% would skip or delay medical care to reduce expenses, and 24% would accumulate medical debt to afford their care.
Cancer patients and survivors must balance reducing their health care costs with ensuring they have comprehensive coverage of services, treatments, and care providers.
The incidence of cancer increases with age and thus the Medicare program is vitally important to millions of Americans who are undergoing active cancer treatment, are cancer survivors or who have not yet developed cancer.
Consumers need access to health insurance policies that cover a full range of evidence-based health care services – including prevention and primary care – necessary to maintain health, avoid disease, overcome acute illness and live with chronic disease. Any health care system that works for cancer patients must have standards ensuring that enrollees have access to comprehensive health insurance.
Current federal requirements prohibit most insurance plans from limiting both the lifetime and annual dollar value of benefits. This ban is one of several important patient protections that must be part of any health care system that works for cancer patients.
While ACS CAN supports South Carolina expanding Medicaid, we oppose the current proposal for a severely limited expansion with work requirements and an enrollment cap. We urge CMS to reject this proposal.
Medicaid provides access to life-saving care for people in America fighting cancer, especially low-income individuals primarily from rural and underserved communities.
ACS CAN and Manatt Health estimated the amount of coverage loss and funding losses that would be caused if the House-passed budget reconciliation bill became law.
